The results of the MS-SMART trial, an innovative trial testing multiple drugs at the same time, have ruled out three repurposed drugs for the treatment of progressive MS.
A treatment that blocks a type of protein that accumulates in the brain was able to reduce inflammation and damage to nerves in laboratory models of MS.
Researchers, clinicians and people living with MS, from around the world converged on the city of Toronto in Canada for the 3rd Congress of the International Progressive MS Alliance.
More than 100 staff, volunteers, and people with and affected by MS from 39 countries gathered in London in September for the MSIF Movement’s 50th Anniversary meetings.
A meeting of minds took place at the recent International Progressive MS Alliance event in London
Matthew Miles, Chief Executive of MS Research Australia, shared insights on how technology is revolutionising research, treatment, diagnosis, and more